70 related articles for article (PubMed ID: 38468260)
21. The Quest to Eradicate HPV-Related Oropharyngeal Carcinoma: An Opportunity Not to Miss.
Lalonde CS; Teng Y; Burtness BA; Ferris RL; Ahmed R; Saba NF
J Natl Cancer Inst; 2022 Oct; 114(10):1333-1337. PubMed ID: 35567531
[TBL] [Abstract][Full Text] [Related]
22. Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways.
Zhang Y; Chen F; Chandrashekar DS; Varambally S; Creighton CJ
Nat Commun; 2022 May; 13(1):2669. PubMed ID: 35562349
[TBL] [Abstract][Full Text] [Related]
23. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.
Herbst RS; Majem M; Barlesi F; Carcereny E; Chu Q; Monnet I; Sanchez-Hernandez A; Dakhil S; Camidge DR; Winzer L; Soo-Hoo Y; Cooper ZA; Kumar R; Bothos J; Aggarwal C; Martinez-Marti A
J Clin Oncol; 2022 Oct; 40(29):3383-3393. PubMed ID: 35452273
[TBL] [Abstract][Full Text] [Related]
24. Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma.
Wise-Draper TM; Gulati S; Palackdharry S; Hinrichs BH; Worden FP; Old MO; Dunlap NE; Kaczmar JM; Patil Y; Riaz MK; Tang A; Mark J; Zender C; Gillenwater AM; Bell D; Kurtzweil N; Mathews M; Allen CL; Mierzwa ML; Casper K; Jandarov R; Medvedovic M; Lee JJ; Harun N; Takiar V; Gillison M
Clin Cancer Res; 2022 Apr; 28(7):1345-1352. PubMed ID: 35338369
[TBL] [Abstract][Full Text] [Related]
25. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing.
Kürten CHL; Kulkarni A; Cillo AR; Santos PM; Roble AK; Onkar S; Reeder C; Lang S; Chen X; Duvvuri U; Kim S; Liu A; Tabib T; Lafyatis R; Feng J; Gao SJ; Bruno TC; Vignali DAA; Lu X; Bao R; Vujanovic L; Ferris RL
Nat Commun; 2021 Dec; 12(1):7338. PubMed ID: 34921143
[TBL] [Abstract][Full Text] [Related]
26. CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells.
Qadir AS; Guégan JP; Ginestier C; Chaibi A; Bessede A; Charafe-Jauffret E; Macario M; Lavoué V; Rouge TM; Law C; Vilker J; Wang H; Stroup E; Schipma MJ; Bridgeman B; Murmann AE; Ji Z; Legembre P; Peter ME
iScience; 2021 Nov; 24(11):103348. PubMed ID: 34816102
[TBL] [Abstract][Full Text] [Related]
27. De-escalation studies in HPV-positive oropharyngeal cancer: How should we proceed?
Golusinski P; Corry J; Poorten VV; Simo R; Sjögren E; Mäkitie A; Kowalski LP; Langendijk J; Braakhuis BJM; Takes RP; Coca-Pelaz A; Rodrigo JP; Willems SM; Forastiere AA; De Bree R; Saba NF; Teng Y; Sanabria A; Di Maio P; Szewczyk M; Ferlito A
Oral Oncol; 2021 Dec; 123():105620. PubMed ID: 34798575
[TBL] [Abstract][Full Text] [Related]
28. Head and neck cancer.
Mody MD; Rocco JW; Yom SS; Haddad RI; Saba NF
Lancet; 2021 Dec; 398(10318):2289-2299. PubMed ID: 34562395
[TBL] [Abstract][Full Text] [Related]
29. Role of the CCL2-CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting.
Xu M; Wang Y; Xia R; Wei Y; Wei X
Cell Prolif; 2021 Oct; 54(10):e13115. PubMed ID: 34464477
[TBL] [Abstract][Full Text] [Related]
30. B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma.
Ruffin AT; Cillo AR; Tabib T; Liu A; Onkar S; Kunning SR; Lampenfeld C; Atiya HI; Abecassis I; Kürten CHL; Qi Z; Soose R; Duvvuri U; Kim S; Oesterrich S; Lafyatis R; Coffman LG; Ferris RL; Vignali DAA; Bruno TC
Nat Commun; 2021 Jun; 12(1):3349. PubMed ID: 34099645
[TBL] [Abstract][Full Text] [Related]
31. Landscape of natural killer cell activity in head and neck squamous cell carcinoma.
Charap AJ; Enokida T; Brody R; Sfakianos J; Miles B; Bhardwaj N; Horowitz A
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428584
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy.
Tu MM; Abdel-Hafiz HA; Jones RT; Jean A; Hoff KJ; Duex JE; Chauca-Diaz A; Costello JC; Dancik GM; Tamburini BAJ; Czerniak B; Kaye J; Theodorescu D
Commun Biol; 2020 Nov; 3(1):720. PubMed ID: 33247183
[TBL] [Abstract][Full Text] [Related]
33. PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model.
Peng S; Tan M; Li YD; Cheng MA; Farmer E; Ferrall L; Gaillard S; Roden RBS; Hung CF; Wu TC
Cancer Immunol Immunother; 2021 Apr; 70(4):1049-1062. PubMed ID: 33108473
[TBL] [Abstract][Full Text] [Related]
34. CCL2/CCR2 signaling in cancer pathogenesis.
Hao Q; Vadgama JV; Wang P
Cell Commun Signal; 2020 May; 18(1):82. PubMed ID: 32471499
[TBL] [Abstract][Full Text] [Related]
35. Asialo GM1-positive liver-resident CD8 T cells that express CD44 and LFA-1 are essential for immune clearance of hepatitis B virus.
Sung CC; Horng JH; Siao SH; Chyuan IT; Tsai HF; Chen PJ; Hsu PN
Cell Mol Immunol; 2021 Jul; 18(7):1772-1782. PubMed ID: 32111985
[TBL] [Abstract][Full Text] [Related]
36. Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer.
Cillo AR; Kürten CHL; Tabib T; Qi Z; Onkar S; Wang T; Liu A; Duvvuri U; Kim S; Soose RJ; Oesterreich S; Chen W; Lafyatis R; Bruno TC; Ferris RL; Vignali DAA
Immunity; 2020 Jan; 52(1):183-199.e9. PubMed ID: 31924475
[TBL] [Abstract][Full Text] [Related]
37. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D;
Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945
[TBL] [Abstract][Full Text] [Related]
38. Monalizumab: inhibiting the novel immune checkpoint NKG2A.
van Hall T; André P; Horowitz A; Ruan DF; Borst L; Zerbib R; Narni-Mancinelli E; van der Burg SH; Vivier E
J Immunother Cancer; 2019 Oct; 7(1):263. PubMed ID: 31623687
[TBL] [Abstract][Full Text] [Related]
39. Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221.
Tinker AV; Hirte HW; Provencher D; Butler M; Ritter H; Tu D; Azim HA; Paralejas P; Grenier N; Hahn SA; Ramsahai J; Seymour L
Clin Cancer Res; 2019 Oct; 25(20):6052-6060. PubMed ID: 31308062
[TBL] [Abstract][Full Text] [Related]
40. Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment.
Oweida AJ; Bhatia S; Van Court B; Darragh L; Serkova N; Karam SD
J Vis Exp; 2019 Apr; (146):. PubMed ID: 31058896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
